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ABSTRACT: Bacteria routinely become resistant to antibiotics through the uptake of plasmids that encode
resistance-mediating proteins. Such plasmid-based resistance is seen extensively in clinical settings and
has been documented for a wide variety of bacterial infections from both Gram-positive and Gram-
negative organisms. We recently reported that a small molecule could be used to mimic a natural process
of plasmid elimination, called plasmid incompatibility, and that the addition of this compound causes
elimination of an IncB plasmid from E. coli and a subsequent resensitization to antibiotics [DeNap, Thomas,
Musk, and Hergenrother (2004) J. Am. Chem. Soc. 126, 15402-15404]. Described herein is a further
substantiation and validation of the notion that plasmid incompatibility can be mimicked with small
molecules that bind to important RNA targets controlling plasmid replication. In this study, the dissociation
constant and stoichiometry of RNA binding are determined for 12 aminoglycosides with stem-loop I
(SLI) of the IncB replication machinery. Importantly, it is found that compounds that do not bind to this
RNA replication control element fail to induce plasmid loss in vivo, whereas those that do bind to the
RNA typically cause measurable plasmid loss. These results highlight the potential for targeting key RNA
regions for induction of plasmid loss and the subsequent resensitization of bacteria to antibiotics.
Bacterial resistance to antibiotics poses a significant threat
to public health (1, 2). The seven major classes of antibacte-
rial agents can be grouped into three broad categories
according to their mechanism of action: ribosome binders
(tetracyclines, aminoglycosides, oxazolidinones, macrolides),
cell wall biosynthesis inhibitors (â-lactams/cephlasporins,
vancomycin), and inhibitors of DNA gyrase (fluoroquino-
lones) (3). Bacterial resistance to these antibiotics is a
constant concern in hospital settings, and notorious bacteria
such as vancomycin-resistant enterococci (VRE)1 and me-
thicllin-resistant Staphylococcus aureus (MRSA) are com-
mon nosocomial pathogens (4, 5). In fact, of drug-resistant
hospital-acquired infections in 2002 almost 60% were
resistant to methicillin, and over 20% were resistant to
vancomycin, generally regarded as the drug of last resort
(6). Paradoxically, as drug-resistant bacteria have become
more pervasive, antibacterial programs at major pharmaceu-
tical companies have been scaled back dramatically (6, 7).
Much of bacterial resistance to antibiotics has arisen
through lateral (sometimes called horizontal) DNA transfer
events (8). In lateral DNA transfer a bacterium acquires a
piece of DNA from another microorganism in a process not
associated with bacterial replication and cell division. This
is in contrast to the standard “vertical” DNA transfer that
takes place in bacterial cell division. Through lateral DNA
transfer a bacterium will often obtain a piece of DNA that
encodes proteins mediating antibiotic resistance. Typically
such proteins either will enable the direct chemical modifica-
tion of the antibiotic (e.g., aminoglycoside kinase, â-lacta-
mase), (9) catalyze the chemical modification of the target
of the antibiotic (e.g., erythromycin methylase) (10, 11), or
assist in actively exporting the antibiotic out of the cell (e.g.,
multidrug-resistant protein pumps) (12, 13). In each of these
cases, acquisition of the foreign DNA ultimately confers on
the host resistance to the antibacterial agent. Although there
are a number of mechanisms for lateral DNA transfer,
plasmid acquisition is among the most common. (8) Plasmids
can be easily transferred from bacteria to bacteria and have
the capacity to replicate in diverse bacterial hosts, enabling
the rapid dissemination of antibiotic resistance genes through-
out a mixed bacterial population.
Plasmid-mediated resistance to antibiotics has been directly
implicated in a multitude of clinical drug-resistant bacterial
infections (14, 15). Plasmid-encoded resistance to â-lactam
antibiotics is ubiquitous and has been observed in a variety
of bacteria including Escherichia coli (16), Enterobacter sp.
(17), Pseudomonas putida (18), Klebsiella pneumoniae (19),
Salmonella (20), Vibrio cholerae (21), and many others (22,
23). Plasmid-mediated resistance to aminoglycosides (24-
27), macrolides (28, 29), and tetracyclines (30) is also quite
common. While resistance to quinolones was once believed
to be conferred solely by chromosomal mutation, plasmid-
encoded resistance to this class of antibiotics was first
reported in 1998 (31), and it is now clear that an increasing
fraction of strains of quinolone-resistant K. pneumoniae
isolated from infected patients harbor resistance-mediating
plasmids (32, 33). Perhaps most troubling is the recent report
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resistance had transferred from Enterococcus faecalis to S.
aureus (14, 34). Vancomycin is the antibiotic of last resort
for many infections, including methicillin-resistant S. aureus
(MRSA); widespread resistance of S. aureus to vancomycin
would be disastrous.
If a systematic method existed to vanquish these plasmids
from bacterial cells, then the bacteria could no longer produce
the resistance-mediating proteins and would be resensitized
to standard antibiotics (35). Plasmid incompatibility, a natural
mechanism for plasmid elimination, offers clues about how
to develop a mechanism-based plasmid elimination agent.
Two plasmids are “incompatible” if they will not stably
cosegregate to daughter cells after bacterial cell division (36,
37). The mechanisms for plasmid incompatibility are well
documented and typically involve the use of a macromo-
lecular “incompatibility determinant” that inhibits the rep-
lication of an incompatible plasmid and controls plasmid
copy number (38, 39). Incompatible plasmids have similar
replication elements and thus compete with one another for
the various macromolecules involved in plasmid replication.
The net result of the introduction of an incompatible plasmid
is that one of the plasmids is not stably replicated and is
thus ultimately not passed onto daughter cells. Although
incompatibility determinants can take several forms, a
common theme in plasmid replication control is the use of
a small, highly structured RNA as the incompatibility
determinant (38, 40, 41).
Plasmids of the IncB group have been extensively studied,
and their mechanism for copy number control and incompat-
ibility have been well characterized. A detailed picture of
their replication has emerged over the last 20 years (Figure
1) (42-51), and they are representative of the large group
of plasmids in which small pieces of RNA dictate incompat-
ibility and control plasmid replication. The replication of
IncB plasmids is ultimately controlled by the cellular levels
of the RepA protein; the production of this protein is rate-
limiting for plasmid replication (52, 53). Accordingly, to
tightly regulate plasmid copy number, the amount of RepA
produced is intricately controlled at the translational level
(48). Upon translation of a leader peptide (RepB), stem-
loop III (SLIII) of the mRNA for RepA is opened, allowing
the binding of SLI and exposing the RepA Shine-Dalgarno
sequence (44, 50, 51). The resulting SLIII-SLI “pseudoknot”
enables ribosome binding and translation of the RepA protein
(47). As a control on plasmid copy number, the small
countertranscript RNA (RNA I) binds to SLI (42, 48, 49).
This binding sequesters key pseudoknot bases, thereby
inhibiting the SLI-SLIII interaction and blocking plasmid
replication (47, 48).
To develop a systematic, mechanism-based approach for
plasmid elimination, we chose to mimic plasmid incompat-
ibility by identifying small molecules that (like RNA I) bind
to SLI. We have recently shown that the aminoglycoside
natural product apramycin will bind tightly to SLI (Kd ) 93
nM) in the critical SLIII binding region (54). In addition,
this compound causes the elimination of an IncB plasmid
encoding â-lactamase from E. coli, resensitizing these
bacteria to ampicillin (54). Mutagenesis of SLI confirmed
that strong binding of apramycin to SLI was essential for its
plasmid elimination effect (54). Thus, apramycin mimics an
incompatible plasmid and causes the elimination of plasmid
from E. coli.
FIGURE 1: The IncB replication machinery (47). Translation of RepB opens SLI, allowing its formation of a psuedoknot with SLIII. The
countertranscript RNAI blocks the SLI-SLIII interaction (and hence plasmid replication) largely by sequestering critical bases on SLI. A
small molecule that binds tightly to SLI could also turn off plasmid replication.
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eliminating effect of aminoglycosides and their affinity for
SLI. In this study, we have determined the dissociation
constants and stoichiometry of binding for a number of
different aminoglycosides with SLI and its mutants. In
addition, we have evaluated the antiplasmid effect of these
compounds on E. coli harboring an IncB plasmid. In general,
we find a correlation between binding affinity and plasmid-
eliminating ability, consistent with the notion that these
compounds induce plasmid elimination by mimicking plas-
mid incompatibility in the bacterial cell.
EXPERIMENTAL PROCEDURES
Materials. All reagents were obtained from Fisher unless
otherwise stated. All solutions were made with Milli-Q
purified water. Aminoglycosides were purchased from
Sigma, and all RNA was purchased with a 5¢-fluorescein
tag from Dharmacon Research. The Bacto-agar and Bacto-
casamino acids were purchased from Becton, Dickinson and
Co. The pin transfer device was purchased from V&P
Scientific, Inc. The strain of E. coli K12 used in this study
is JP4821 (thi-1 thr-1 aroL513 leuB6 gyrA379 gal-351
lacZDM15 lacY1 tonA21 supE44 nalA hsdR). The plasmid
used in this study is pMU2403. Both were obtained from
Professor A. J. Pittard (48).
Fluorescence Binding Assays. The ligand solutions were
prepared as serial dilutions in TM1 buffer (10 mM Tris, 1
mM MgCl2, pH 7.5) at a concentration four times greater
than the desired final concentration to allow for the subse-
quent dilution during the addition of the RNA solution. The
appropriate ligand solution (25 íL) was then added to a well
of a black 96-well plate (Nunc 237105), in triplicate.
Refolding of the RNA was performed using a thermocycler
as follows. The RNA, stored in 10 mM Tris and 0.5 mM
EDTA, pH 7.5, was first denatured by heating to 95 °C for
2 min; the temperature was then lowered to 4 °C for 5 min
followed by incubation at room temperature for 15 min. After
refolding, the RNA was diluted to a working concentration
of 37.5 nM through addition of the appropriate amount of
TM1 buffer (<5 íL added into 3000 íL of buffer). The tube
was mixed by inversion, and 75 íL of the RNA solution
was added to each well containing ligand. This subsequent
dilution lowered the final RNA concentration to 28 nM. The
fluorescence was measured on a Criterion Analyst AD
(Molecular Devices) with an excitation filter of 485 ( 15
nm, an emission filter of 530 ( 15 nm, and a 505 nm
dichroic cutoff mirror. Binding was allowed to proceed for
30 min to achieve equilibrium. Equilibrium was determined
when three identical curve were obtained. All curves were
fit to a single site model using TableCurve 2D v5.01
(equation 8108):
where y is the fraction bound, x is the ligand concentration,
and a is the asymptotic limit.
Job Plot. The Job plot, or method of continuous variation,
requires that the total concentration of ligand and receptor
be at least five times that of the Kd (55). In an effort to reduce
the amount of RNA consumed, each Job plot was performed
such that the total concentration of the ligand and RNA was
kept at five times the Kd for the particular aminoglycoside-
RNA pair. To a well of a black 96-well plate (Nunc 237105),
50 íL of the appropriate ligand concentration was added to
150 íL of the appropriate RNA concentration. In the
fluorescence-based assay binding is determined by the change
in fluorescence relative to the unbound state. Thus, each well
that contains ligand and RNA must have a control well that
contains only RNA at the appropriate concentration as a
reference point. Each bar on the graph in Figure 4 represents
the change in fluorescence observed, which was obtained
by subtracting the fluorescence RNA-ligand well from the
fluorescence of RNA alone well.
Determination of MIC Values. The MIC values of the
aminoglycosides were determined by growing E. coli JP4821
containing plasmid pMU2403 diluted to 105 colony forming
units (CFU)/mL in the presence of varying concentrations
of the aminoglycosides (0, 0.5, 1, 2, 4, 8, 16, 32, 64, 128,
256, and 512 íg/mL) for 24 h in the wells of a 96-well plate
(in duplicate) and determining the lowest concentration at
which no bacterial growth occurred (as determined by OD600
reading). The MIC values are as follows: hygromycin B )
128 íg/mL; sisomicin ) 2 íg/mL; spectinomycin ) 64 íg/
mL; neomycin B ) 16 íg/mL; tobramycin ) 4 íg/mL;
kanamycin A ) 16 íg/mL; kanamycin B ) 8 íg/mL;
butirosin B ) 16 íg/mL; amikacin ) 32 íg/mL; paromo-
mycin I ) 32 íg/mL; gentamicin ) 4 íg/mL; apramycin )
32 íg/mL.
Growth of Bacteria in 96-Well Plates for Plasmid Elimi-
nation Determinations. A single colony from a streak plate
of E. coli JP4821 containing plasmid pMU2403 was added
to 10 mL of minimal media (MM) in a 50 mL conical tube.
M63 medium was used, prepared as instructed in ref 89
except that 2 glucose was used. The culture was shaken at
225 rpm overnight at 37 °C, and the overnight culture was
used to begin twelve 10 mL cultures, each containing an
aminoglycoside at the given concentration (60% of their
MIC) or no aminoglycoside (for control). After growing
overnight, these cultures were transferred to the wells of a
96-well plate (16 wells per aminoglycoside, 200 íL per well),
and a pin transfer device was used to transfer 200 nL from
this 96-well plate into a 96-well plate containing fresh media/
aminoglycoside. Sixteen wells were grown in the absence
of aminoglycoside as controls. After being incubated over-
night, the OD600 was read before pin transferring the cultures
to the next plate at a 106 dilution (this is the first passaging).
The plasmid-eliminating ability of the aminoglycosides was
evaluated at the following concentrations: hygromycin B
) 70 íg/mL; sisomicin ) 1.6 íg/mL; spectinomycin ) 57
íg/mL; neomycin B ) 8 íg/mL; tobramycin ) 2 íg/mL;
kanamycin A ) 8 íg/mL; kanamycin B ) 6 íg/mL;
butirosin B ) 10 íg/mL; amikacin ) 12 íg/mL; paromo-
mycin I ) 18 íg/mL; gentamicin ) 2 íg/mL; apramycin )
18 íg/mL.
Determination of Plasmid Loss. After 24 passagings at
11 generations per passage (as determined by dilution
plating) plasmid loss was determined by diluting an aliquot
of culture from each of the wells and plating it onto a MM
agar plate containing the appropriate aminoglycoside. After
the colonies were allowed to grow overnight, the plates were
photographed before being replicated onto plates identical
to the master except for the presence of ampicillin at 100
íg/mL. After the replicas had grown, the number of colonies
that did not replicate was determined visually. By totaling
y ) ax/Kd+ x
6802 Biochemistry, Vol. 44, No. 18, 2005 Thomas et al.the number of nonreplicating colonies and dividing that by
the total number of colonies, the percent loss is determined.
On average, 2400 master plate colonies were counted for
each determination in Figure 5.
RESULTS
Binding of Aminoglycosides to SLI. Given the recent
success using apramycin to eliminate an IncB plasmid from
E. coli and the known general proclivity for aminoglycosides
to bind RNA (56, 57), we investigated in detail the binding
of other aminoglycosides to SLI in vitro and their ability to
eliminate plasmids in vivo. Assessment of binding constants
for small molecule-RNA interactions poses a considerable
challenge, as there is no universal and convenient readout
in a binding assay. Although binding determination methods
based on the displacement of a fluorescently labeled ligand
(58-60), isothermal titration calorimetry (61, 62), the
utilization of surface plasmon resonance (63, 64), or mass
spectrometry (65) have been described, a more general
protocol is the use of a fluorescently labeled RNA. This
fluorescent label can be introduced either through an un-
natural RNA base or via an end label (66-68). In this
method, the conformational change of the RNA upon binding
to the small molecule is read out as either a quench or an
increase in fluorescence (66). Structural and biochemical data
indicate that RNA often experiences a large conformational
change upon small molecule binding (66, 69, 70). In addition,
the end-label method for determination of small molecule-
RNA dissociation constants has been validated in control
experiments (71),and is used broadly (67, 68, 72-74). Thus,
the binding of aminoglycosides to SLI was assessed through
the use of a 5¢-fluorescein-labeled version of SLI. This
fluorescein-labeled RNA was then incubated with various
concentrations of the aminoglycoside, and the change in
fluorescence was monitored and a corresponding dissociation
constant calculated.
The structures of the aminoglycosides employed in this
study are displayed in Figure 2. The structure of SLI is shown
in Figure 3A, and the residues that form the pseudoknot with
SLIII are shown in bold. Binding curves of SLI with two
aminoglycosides are shown in Figure 3B (see Supporting
Information for the remaining binding curves). As revealed
in Table 1, the aminoglycosides appear to fall into two classes
with respect to their affinity for SLI RNA. Two compounds
(hygromycin B and spectinomycin) do not bind to the RNA
within the concentration range tested and have dissociation
constants greater than 4 íM. The second class of aminogly-
cosides (butirosin B, apramycin, amikacin, neomycin B,
kanamycin A, kanamycin B, gentamicin, tobramycin, siso-
micin, paromomycin I) bind to SLI with dissociation
constants ranging from 0.03 to 0.17 íM. It is notable that
such Kd values are quite low, even for an aminoglycoside-
RNA interaction, possibly indicative of a conformation of
SLI that is favorable for aminoglycoside binding. Dissocia-
tion constants for aminoglycosides and various RNAs are
typically in the low micromolar range (58), although there
are some exceptions to this (75).
FIGURE 2: Aminoglycosides used in this study.
Antiplasmid Effect of Aminoglycosides Biochemistry, Vol. 44, No. 18, 2005 6803Binding of Aminoglycosides to SLI Mutants. To decipher
which individual bases of SLI are important for binding the
aminoglycosides, mutations at positions in and around the
SLIII binding site were created, and their binding to the
aminoglycosides was evaluated (Table 1). We chose to create
double mutations with transitions of the base pairs under
evaluation (purine to purine, pyrimidine to pyrimidine). In
general, the majority of these mutations had little or no effect
on aminoglycoside binding; the double mutations at positions
15 and 16, 17 and 18, 19 and 20, and 21 and 22 did not
significantly alter the dissociation constants of the various
aminoglycosides. However, in all cases the double mutant
of positions 22 and 23 essentially abolished the binding of
the aminoglycosides to this stem-loop. This result is
consistent with that previously observed with apramycin (54)
and suggests that the aminoglycosides share a common
binding site on SLI.
Stoichiometry of Aminoglycoside-RNA Binding.T od e -
termine the precise stoichiometry of the aminoglycoside-
SLI interactions, binding was evaluated at a variety of molar
ratios, and Job plots were constructed. In the Job plot, the
ratios of ligand and receptor are varied while the combined
concentration of the two remains constant. The observed
binding is then plotted as a function of the varying ratio.
The maximum occurs at the stoichiometric ratio of the ligand
and receptor, that is, the maximum defines the stoichiometry
of binding (55, 76, 77).
Analysis of the aminoglycoside-SLI interactions via this
method revealed a 1:1 stoichiometry of binding for all
compounds evaluated. The Job plots for gentamicin and
tobramycin are displayed in Figure 4, and the graphs for
butirosin B, amikacin, neomycin B, kanamycin A, kanamycin
B, sisomicin, paromomycin I, and apramycin are in the
Supporting Information. Again, analysis of the Job plot data
is consistent with a common binding site for the aminogly-
cosides that bind to SLI.
Antiplasmid Effect of Aminoglycosides. Previously, we
have shown that apramycin causes significant loss of the IncB
plasmid pMU2403 from E. coli (54). In addition, a plasmid
containing the A22G, A23G mutations on SLI that abolish
the apramycin binding site was not eliminated with apra-
mycin. To further define the relationship between the
antiplasmid effect and aminoglycoside-SLI binding, ami-
noglycosides with a range of affinities for SLI were sought.
As described above, we now have determined that several
aminoglycosides will bind tightly to SLI, and mutagenic data
indicate that they share a common binding site. As impor-
tantly, we have also identified two aminoglycosides, hygro-
mycin B and spectinomycin, which do not bind to SLI with
any appreciable affinity. Therefore, these compounds offer
an excellent opportunity as controls to confirm the hypothesis
that the plasmid elimination effect is linked to SLI binding
propensity.
To evaluate the antiplasmid effect of the various ami-
noglycosides, E. coli harboring plasmid pMU2403 was
grown for 250 generations in the presence of the compound
being tested. To reach 250 generations, bacteria were grown
for 10-12 generations (in the presence of the putative
antiplasmid agent), at which point a small portion was
transferred to fresh media. This cycle was repeated 24 times
to give a total of approximately 250 elapsed bacterial
generations over the course of the experiment. Plasmid loss
was determined by plating bacteria onto nonselective media
(containing the putative antiplasmid agent but no antibiotic)
followed by replica plating onto media containing ampicillin
(100 íg/mL) and the compound under evaluation. As
apramycin was found to be the most effective at plasmid
FIGURE 3: (A) Sequence and secondary structure of SLI of the IncB replication system. Residues in bold are those that are complementary
to SLIII. (B) Binding of gentamicin and tobramycin to 5¢-fluourescein-labeled SLI.
Table 1: Kd Values for Binding of Aminoglycosides to
Fluorescently Labeled SLI and Several of Its Mutantsa
Fl-SLI
(íM)
U15C,
U16C
(íM)
G17A,
G18A
(íM)
C19U,
G20A
(íM)
G21A,
A22G
(íM)
A22G,
A23G
(íM)
butirosin B 0.20 0.20 0.20 0.15 0.26 >4.00
amikacin 0.08 0.07 0.13 0.07 0.12 >4.00
neomycin B 0.08 0.07 0.05 0.05 0.03 >4.00
kanamycin B 0.11 0.11 0.10 0.10 0.13 >4.00
kanamycin A 0.17 0.29 0.12 0.30 0.24 >4.00
gentamicin 0.08 0.06 0.10 0.07 0.09 >4.00
tobramycin 0.04 0.09 0.03 0.06 0.07 >4.00
hygromycin B >4.00 ND ND ND ND ND
sisomicin 0.03 0.04 0.04 0.03 0.06 >4.00
spectinomycin >4.00 ND ND ND ND ND
paromomycin I 0.04 0.04 05 0.05 0.05 >4.00
a For the structure of SLI, see Figure 3A. ND ) not determined.
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of its MIC (54), all compounds were assessed at ap-
proximately 60% of their MIC. The MIC values for each
compound are listed in the Experimental Procedures.
The data on the antiplasmid effect of the aminoglycosides
are displayed in Figure 5; for reference, their relative
affinities for SLI are also displayed on this graph. In general,
compounds that showed affinity for SLI and could be tested
at relatively high concentrations (such as paromomycin I,
butriosin B, amikacin, kanamycin A, and kanamycin B)
showed a significant degree of plasmid loss after 250
bacterial generations.
More striking is the correlation between the in vitro
binding data and the in vivo antiplasmid effect for hygro-
mycin B and spectinomycin. Neither of these compounds
binds to SLI to an appreciable extent, and they were both
unable to effect any elimination of plasmids from the
bacterial cell, even at fairly high concentrations (70 and 57
íg/mL for hygromycin B and spectinomycin, respectively).
These data are consistent with the notion that the strong
antiplasmid effect observed for apramycin is due to its SLI-
binding properties and not to some other general stress effect.
Sisomicin is an outlier as it binds strongly to SLI but does
not induce an appreciable plasmid loss after 250 generations
of bacterial growth. This compound is also quite toxic to E.
coli, with a MIC of 2 íg/mL, and likely does not effect
plasmid elimination due to off-target effects (see Discussion
below).
DISCUSSION
Mimicking the natural process of plasmid incompatibility
with a small molecule is a potentially general strategy for
effecting plasmid elimination from bacterial cells. The IncB
group of plasmids have been meticulously characterized both
biochemically and genetically and thus provide an ideal
proving ground for this approach. Furthermore, there is
considerable homology in the key regulatory region of SLI
of IncB with plasmids from a number of other systems (78,
79). Gerdes and co-workers have recently reported a
systematic comparison of loops in RNA-regulated gene
systems from a variety of plasmids (78, 79). From this
analysis the YUNR motif was found to be common in the
loop region, and SLI of an IncB plasmid was one of the
RNAs analyzed; the YUNR in SLI correspond to residues
U15, U16, G17, and G18 of Figure 3A. Thus, compounds
that are effective against one incompatibility type have
potential to be more broadly applicable.
In this study we set out to determine if there was a
correlation between the ability of a small molecule to bind
to SLI of the mRNA for the RepA protein in the IncB system
and its influence on plasmid stability in vivo. Thus, multiple
aminoglycosides (compounds that have a proclivity for
binding RNA) were evaluated for their ability to bind SLI
in vitro. While many compounds were found to bind to SLI
FIGURE 4: Stoichiometry of small molecule-RNA binding as revealed by Job plots.
FIGURE 5: SLI-binding aminoglycosides generally cause plasmid
elimination from E. coli harboring pMU2403. Gray bars indicate
the percentage of plasmid loss after incubation with the given
compound for 250 bacterial generations; percentages were deter-
mined by replica plating. Black bars indicate relative affinities of
the aminoglycosides for the SLI RNA, as determined by the
fluorescence assay described in the Results section. Sisomicin binds
tightest, with a dissociation constant of 0.03 íM. Compounds that
are unable to bind to SLI (such as spectinomycin and hygromycin
B) show no appreciable antiplasmid effect. See Experimental
Procedures for exact concentrations of aminoglycosides used in
plasmid elimination experiments.
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íM), two aminoglycosides (spectinomycin and hygromycin)
showed no detectable binding. This discovery of aminogly-
cosides that do not bind SLI was important, as it allowed
for testing the general stress of aminoglycosides on E. coli,
in the absence of SLI binding. If aminoglycosides exerted
their antiplasmid effect by induction of a simple bacterial
stress response, then any aminoglycoside would be expected
to have this effect. However, if the antiplasmid effect was
truly a mechanism- and target-based phenomenon, then
aminoglycosides that do not bind to the antiplasmid target
(in this case SLI) should no longer be effective antiplasmid
agents.
As detailed herein, compounds that bind tightly to SLI
cause plasmid elimination to various extents; the only
exception to this is sisomicin (discussed further below).
Importantly, the two compounds that show no detectable
affinity for SLI in vitro also cause no plasmid loss in vivo
(Figure 5). These data are consistent with the notion that
the aminoglycosides that do bind to SLI and cause plasmid
elimination do so by binding to SLI in vivo. In this vein, we
have previously shown that mutagenic elimination of the
critical apramycin binding site on SLI results in a plasmid
that can no longer be eliminated by apramycin (54);
analogous experiments have shown that gentamicin also fails
to effect plasmid elimination of this mutant plasmid (data
not shown). The combined analysis of these experiments
indicates that apramycin and certain other aminoglycosides
cause elimination of the IncB plasmid by binding to SLI in
a fashion that mimics the plasmid incompatibility process.
There is a rich history of testing aminoglycosides for
binding to various RNA targets in vitro (56, 57, 80). Thus,
there is an opportunity to compare aminoglycoside-SLI
binding to that of other known aminoglycoside-RNA
interactions. Most relevant to the work discussed herein are
experiments in which the affinity of aminoglycosides for
bacterial targets (such as the A-site of the 16S ribosomal
RNA) has been assessed. In general, the aminoglycosides
depicted in Figure 2 bind to the A-site of the 16S bacterial
ribosomal RNA with dissociation constants ranging from 0.2
to 2.0 íM( 56, 81, 82), with some variation in the values
depending on the precise conditions and the method of
analysis. Therefore, the affinities observed for aminoglyco-
sides with SLI (0.1 íM) may indeed allow for specificity
in vivo and likely account for the antiplasmid, but not
antibiotic, properties of the aminoglycosides at the concen-
trations tested.
However, aminoglycosides are known to have some
promiscuity in their RNA binding (63). It is thus quite
possible that the lack of a precise correlation between SLI
binding and plasmid elimination is due to some off-target
effects of the aminoglycosides. For example, sisomicin binds
strongly to SLI but induces virtually no plasmid loss (Figure
5). However, sisomicin is a potent antimicrobial agent and
has been reported to bind to the formylmethionyl-transfer
RNA (fMet-tRNAfMet) of bacteria in an extremely tight
manner, with a IC50 of 0.7 nM (83); this is one of the
strongest aminoglycoside-RNA interactions ever reported.
Thus, for a compound like sisomicin, which has another high
affinity in vivo target, even a relatively strong affinity for
SLI is overridden, and no plasmid elimination is observed.
As with any medicinal approach that aims to target a single
macromolecule within the cell, the success of a given
compound as an antiplasmid agent will be dictated both by
its affinity and its specificity for SLI. Although such
specificity challenges also exist for protein-based targets, the
small molecule targeting of a single RNA in the cell has
proven quite difficult and remains an active area of inves-
tigation (80, 84, 85). In fact, other than apramycin binding
to SLI of the mRNA of RepA and exerting the antiplasmid
effect, there are precious few examples of exogenously added
small molecules that regulate mRNA function in vivo. On
the other hand, substantial precedent for mRNA targeting
exists with endogenously produced small molecules, as
exemplified by riboswitches (86, 87).
This mechanism-based approach to inhibiting plasmid
replication and inducing plasmid loss from a bacterial
population likely has benefits over other systems where
simple bacterial stress causes plasmid loss (88). However,
as even the most potent compound identified at this point
requires approximately 200 elapsed bacterial generations
before significant plasmid loss is observed (54), a validation
of this approach in an animal model may require the
development of more potent small molecule binders for SLI.
This study further demonstrates and substantiates the
notion that plasmid incompatibility can be mimicked with
small drug-like organic compounds. As plasmids are com-
monly classified according to their incompatibility groups,
in principle, this approach could be applied to any plasmid
system. Such extensions of small molecule mimics of
plasmid incompatibility to other plasmids and other organ-
isms are in progress and will be reported in due course.
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